自然抗肥胖剂的纳米载体支持的输送
Yu-Kuo Chung1, Ching-Yun Hsu2,3, Yu-Ting Wang4
1Graduate Institute of Biomedical Sciences, Chang Gung University, Taoyuan, Taiwan.
Nanomedicine (London, England)
|July 21, 2025
概括
肥胖是一个全球性流行病. 纳米技术增强了用于治疗肥胖和相关疾病的天然化合物,克服了当前治疗方法的局限性并提高了生物可用性.
科学领域:
- 生物医学科学 生物医学科学
- 药理学 药理学是指药理学的学科.
- 纳米技术 纳米技术
背景情况:
- 肥胖是一个全球流行病,与代谢综合征,心血管疾病,2型糖尿病,NAFLD和癌症有关.
- 目前的肥胖治疗方法有其局限性,包括效率差,不良反应和患者服从度低.
- 自然化合物表现有前途,但面临着诸如溶解性差,生物可用性和潜在毒性等挑战.
研究的目的:
- 审查天然化合物对肥胖和相关疾病的治疗潜力.
- 突出纳米技术在提高天然抗肥胖剂疗效方面的作用.
- 讨论纳米启用肥胖治疗的挑战和未来方向.
主要方法:
- 在PubMed,Scopus和谷歌学者的文学评论.
- 专注于天然生物活性,肥胖和纳米粒子辅助药物输送.
- 基于纳米技术的输送系统 (脂质体,纳米粒子等) 的分析. ) 的情况.
主要成果:
- 天然化合物为与肥胖相关的并发症提供了多重目标的作用.
- 纳米配方显著提高了天然化合物的可溶性,生物可用性和治疗功效.
- 纳米技术解决了天然化合物的局限性,增强了它们的抗肥胖作用.
结论:
- 基于纳米技术的输送系统对于实现天然化合物对抗肥胖的全部治疗潜力至关重要.
- 纳米启用策略为克服当前治疗局限性提供了一个有希望的途径.
- 需要进一步的研究来将这些纳米启用策略转化为肥胖管理的临床实践.
相关概念视频
01:16Drug Delivery: Overview
426
The selection of a drug's delivery route depends upon its physicochemical properties, including lipid or water solubility and ionization, as well as the therapeutic requirement, such as immediate or sustained effect. These routes can be divided into three primary categories: enteral, parenteral, and topical.
Enteral delivery involves administering drugs directly through swallowing, sublingual placement, or buccal application. Orally administered drugs predominantly navigate the...
Enteral delivery involves administering drugs directly through swallowing, sublingual placement, or buccal application. Orally administered drugs predominantly navigate the...
426
01:24Obesity
621
The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
621
01:22Drug Delivery: Miscellaneous Routes
468
Drug delivery methods like oral inhalation, nasal sprays, transdermal patches, eye drops, intravitreal injection, and rectal administration provide localized effects with reduced toxicity.
Oral inhalation and nasal sprays swiftly transfer drugs across the respiratory epithelium's mucosal layer. Inhaled glucocorticoids and bronchodilators directly target lung conditions such as asthma, while fluticasone nasal spray mitigates allergic rhinitis.
Transdermal patches transport drugs...
Oral inhalation and nasal sprays swiftly transfer drugs across the respiratory epithelium's mucosal layer. Inhaled glucocorticoids and bronchodilators directly target lung conditions such as asthma, while fluticasone nasal spray mitigates allergic rhinitis.
Transdermal patches transport drugs...
468
01:19Drug Absorption Mechanism: Carrier-Mediated Membrane Transport
4.5K
Certain large, lipid-insoluble drug molecules that resemble amino acids, peptides, or glucose, require specialized carrier proteins to facilitate their diffusion across cell membranes. This transport can occur through either facilitated diffusion, which does not require energy input, or active transport, which does require energy input.
Facilitated diffusion is a passive process that utilizes human Solute Carrier (SLC) transporters. These transporters bind to the drug, undergo structural...
Facilitated diffusion is a passive process that utilizes human Solute Carrier (SLC) transporters. These transporters bind to the drug, undergo structural...
4.5K
01:18Drug Delivery: Enteral Route
736
The enteral drug administration involves three primary routes: oral, sublingual, and buccal. Oral ingestion is the most prevalent, safe, economical, and convenient method for drug administration. However, it has certain drawbacks, including limited absorption due to the drug's low water solubility or poor membrane permeability, possible emesis from GI mucosa irritation, destruction of drugs by digestive enzymes or low gastric pH, and irregular absorption along with food or other drugs.
736
01:24Glucagon-like Receptor Agonists
421
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
421